ArticleInternational journal of clinical oncology2026
Trends and current status in anticancer therapy for older patients with non-small cell lung cancer in Japan, 2016-2021.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionAnticancer therapy for non-small cell lung cancer in patients ≥ 75 years has evolved with accumulating evidence. Recent guidelines recommend that treatment decisions be based on functional status rather than age alone. However, disparities in treatment rates persist between those above and below 75 years. This study examined whether evidence supporting treatment in older patients influences implementation, comparing trends over time by age groups.
methodsA hospital-based cancer registry covering designated cancer centers was linked with a Diagnosis Procedure Combination database, which records all medical interventions at each facility, capturing approximately 50% of lung cancer cases in Japan. For patients ≥ 75 years with good performance status, the implementation rates of standard anticancer therapy were analyzed by disease stage in 2021 and trends from 2016 to 2021.
resultsIn 2021, all standard treatments, except oral molecular-targeted therapies for patients with unresectable cancer, were administered less frequently to those ≥ 75 years. Treatments with evidence established before 2016 were stable throughout the study period. Oral molecular-targeted therapies demonstrated no age-related differences, and adjuvant cytotoxic chemotherapy was less frequently administered to patients ≥ 75 years. In contrast, treatments validated in patients ≥ 75 years after 2016 demonstrated a significant trend towards higher implementation, approaching that in younger patients. Immune checkpoint inhibitors, for which safety and efficacy in older patients remain uncertain, exhibited increasing divergence in implementation rates between age groups over time.
conclusionEvidence supporting the efficacy and safety of therapies in individuals ≥ 75 years may influence treatment selection over time.
Indexed as
Identifiers
41945002What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.